Eli Lilly

(Newser) - The first human trial of a new medication to treat schizophrenia that works fundamentally differently from its predecessors has shown promising results, according to this month's Nature Medicine. The drug targets glutamate rather than dopamine, as do other drugs. Scientists have long known glutamate is involved in schizophrenia.